Analyst firms · H.C. Wainwright · ARCT
H.C. Wainwright ARCT price target and rating history
Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care
H.C. Wainwright rates Arcturus Therapeutics Holdings Inc. (ARCT) Neutral with a $12 price target, as of its latest action on Oct 24, 2025. It has published 3 rating actions on ARCT since May 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
- Current rating
- Neutral
- Price target
- $12
- Median target, all firms
- $20
- Actions on ARCT
- 3
H.C. Wainwright price target on ARCT
Every H.C. Wainwright rating on ARCT
- Oct 24, 2025
- Sep 4, 2025
- May 11, 2023
How other firms rate ARCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $20 | Sep 24, 2026 |
| B. Riley Securities | Buy | $22 | Mar 18, 2026 |
| Roth Capital | Buy | $20 | Jan 23, 2026 |
Questions about H.C. Wainwright and ARCT
- What is H.C. Wainwright's price target for ARCT?
- H.C. Wainwright's latest stated price target for Arcturus Therapeutics Holdings Inc. (ARCT) is $12, from its action on Oct 24, 2025.
- What is H.C. Wainwright's rating on ARCT?
- H.C. Wainwright rates ARCT Neutral, a neutral rating, as of Oct 24, 2025.
- When did H.C. Wainwright last change its view on ARCT?
- On Oct 24, 2025, H.C. Wainwright downgrades to Neutral from Buy, price target $12.
- How does H.C. Wainwright's ARCT target compare with other analysts?
- Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
More ARCT rating histories
All H.C. Wainwright ratingsARCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.